🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →
S&P 500: 659.80 -0.3% NASDAQ 100: 593.02 -0.3% Dow Jones: 461.06 -0.4%

Johnson & Johnson - Q4 2025 13F Filings

JO

Johnson & Johnson

CIK: 0000200406
Address: New Jersey New Brunswick One Johnson & Johnson Plz
$554.63 M
Portfolio Value
17
Assets Held
Reporting Period: Q4 2025
Filing Status:
Active
Last Updated: 03/18/2026

Portfolio Summary (Q4 2025)

View Full Portfolio Analysis

Top Buys

Q4 2025
1. Adicet Bio
+$191,803

Top Sells

Q4 2025

Asset Allocation

Stocks/ETFs
+10.11%
$554.63 M 100.00%
Options
$0 0.00%
Debt
$0 0.00%
Other
$0 0.00%

Sector Allocation (Stocks)

Johnson & Johnson Q4 2025 Filing Summary

Johnson & Johnson originally filed its 13F report for Q4 2025 on February 13, 2026. The filing was subsequently amended, with the latest update submitted on March 18, 2026. The portfolio totaled 554.63 M reflecting a +10.11% change from the prior quarter, spanning 17 assets. The top 10 holdings comprised 98.4% of the portfolio, with Financials as the largest sector allocation. Quarterly activity included 1 new positions and 4 complete exits.

Report Type

Status

Data Summary

Items:

Total Value:

Actions

Issuer Name Class Value Shares Option Type

FAQs for Johnson & Johnson’s Q4 2025 Filing

Yes. Johnson & Johnson originally filed on 02/13/2026 and subsequently submitted 1 amendment(s). The latest filing (13F-HR/A) was submitted on 03/18/2026.

In the Q4 2025 filing, Johnson & Johnson reported a managed portfolio value of 555.05 M, consisting of 17 individual positions.

Multiple filings indicate that Johnson & Johnson updated their Q4 2025 report. The initial filing was submitted on 02/13/2026, followed by amendments to correct data or disclose previously confidential holdings.

This page displays the raw filing documents. To see which stocks Johnson & Johnson bought or sold during Q4 2025, please visit Johnson & Johnson's Portfolio Analysis page.